Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections
Pharmaceutics · 28.04.2025 · 17 (5) · 581
DOI: 10.3390/pharmaceutics17050581 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 28.04.2025. Verfasst von Mohamed Halawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Biosimilars represent medicinal products that exhibit a high degree of similarity to an already sanctioned reference biologic agent, with negligible clinically significant disparities concerning safety, purity, or potency. These therapeutic modalities are formulated as economically viable substitutes for established biologics, thereby facilitating increased accessibility to sophisticated treatments for a range of medical conditions, including infectious diseases caused by bacterial, fungal, and viral pathogens. The current landscape of biosimilars includes therapeutic proteins, such as monoclonal antibodies, antimicrobial peptides, antiviral peptides, and antifungal peptides. Here, we discuss the obstacles inherent in the development of biosimilars, including the rapid mutation rates of pathogens. Furthermore, we discuss innovative technologies within the domain, including antibody engineering, synthetic biology, and cell-free protein synthesis, which exhibit potential for improving the potency and production efficiency of biosimilars. We end with a prospective outlook to highlight the importance and capacity of biosimilars to tackle emerging infectious diseases, highlighting the imperative need for ongoing research and financial commitment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria P.O. Box 21521, Egypt.
ORCID-Profile: Mohamed Halawa, Valerie J Carabetta
Förderung
- NIGMS NIH HHS
- NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Halawa, M., ElSayed, R. M. R., Aderibigbe, T., Newman, P. M., Reid, B. E., & Carabetta, V. J. (2025). Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections. Pharmaceutics, 17(5), 581. https://doi.org/10.3390/pharmaceutics17050581
Vancouver
Halawa M, ElSayed RMR, Aderibigbe T, Newman PM, Reid BE, Carabetta VJ. Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections. Pharmaceutics. 2025;17(5):581. doi:10.3390/pharmaceutics17050581
BibTeX
@article{Halawa2025,
author = {Halawa, Mohamed and ElSayed, Ramez M Rashad and Aderibigbe, Tope and Newman, Precious M and Reid, Briana E and Carabetta, Valerie J},
title = {Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {5},
pages = {581},
doi = {10.3390/pharmaceutics17050581}
}
EUVIMED